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Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium
of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents
the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of
BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular
endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis
process and their expression on tumor samples has been explored as prognostic marker in both
cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs
and evidenced that aberrations in several genes enrolled in the pro-angiogenic signaling, such as FGF
receptor-2 (FGFR-2), are characteristic of BTCs. New drugs targeting the signaling pathways involved
in angiogenesis have been tested in preclinical studies both in vitro and in vivo with promising results.
Moreover, several clinical studies tested monoclonal antibodies against VEGF and tyrosine kinase
inhibitors targeting the VEGF and the MEK/ERK pathways. Herein, we evaluate both the pathogenic
mechanisms of BTCs focused on angiogenesis and the preclinical and clinical data available regarding
the use of new anti-angiogenic drugs in these malignancies.
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1. Introduction
Biliary tract cancers (BTCs) comprise cholangiocarcinoma (CCA), arising from the epithelial
lining of the bile ducts, and gallbladder cancer (GBC). CCA can be subclassified into intrahepatic
(iCCA) and extrahepatic cholangiocarcinoma (eCCA), depending on the origin from the biliary tree
within the liver or outside the liver parenchima [1]. eCCA also comprises perhilar CCA (pCCA),
which is a subset involving the bifurcation of the ducts [2]. iCCA, pCCA and eCCA are distinct
entities that require specific management. They are classified by different WHO classification and
AJCC/UICC TNM staging and are linked to distinct risk factors [3,4]. Furthermore, iCCA and eCCA
are characterized by different pathological features, with iCCA predominantly mass-forming and
pCCA often periductal-infiltrating. Most CCA and GBC are adenocarcinoma and are graded according
to the percentage of glandular tissue [4].
BTCs represent 10%–15% of primary liver cancers and CCA is the second most common primary
liver tumor worldwide after hepatocellular carcinoma (HCC) [5]. Prognosis of advanced and metastatic
BTCs is poor with a five-year survival rate of about 2% for stage IV intrahepatic, extrahepatic bile
duct and gallbladder cancer [6]. Management of early stage and locally-advanced BTCs includes
surgery and chemo-radiotherapy while systemic chemotherapy is the main treatment of metastatic
disease. The cisplatin/gemcitabine combination represents the standard of care and the ABC-02 trial
demonstrated that the combination therapy offers a median survival of 11.7 months as compared with
8.1 months for the gemcitabine-only group [7]. A second-line treatment demonstrated a limited value
in this setting of patients, with a response rate of 10.2% in a retrospective study enrolling 174 patients
pre-treated with the cisplatin/gemcitabine combination [8].
Pathogenesis of BTCs involves several mechanisms whose investigation could be crucial in
the identification of new potential therapeutic targets. Experimental data suggest that a chronic
inflammatory status in the biliary tract promotes the malignant transformation of cholangiocytes [9,10].
In particular, cytokines and growth factors assume the main role in promoting the cancerogenesis in
the biliary tract through the damage of mismatch repair genes, tumor suppressor genes and oncogenes.
Indeed, cytokines activate the nitric oxide synthase favoring the production of reactive nitrogen oxide
species that interact with DNA.
The microenvironment also plays a key role in the pathogenesis of BTCs promoting the tumor
angiogenesis, invasion and metastasis. Cancer-associated fibroblasts promote tumor growth and
angiogenesis through the production of several molecules, including vascular endothelial growth
factor (VEGF), fibroblast growth factor (FGF), and interleukin-6 (IL-6) [11]. Moreover, the production
of VEGF-A, IL-10 and transforming growth factor beta (TGFβ) causes the polarization of macrophage
toward the pro-angiogenic phenotype M2 [12].
The aim of this review is to describe the role of angiogenesis in the pathogenesis of BTCs. These
tumors, especially CCA, are often grey-white scyrrous masses with a poor vascularization, unlike
hepatoarcinoma. However, recent studies focused on the role of pro-angiogenic pathways in BTCs
pathogenesis. Then, the role of anti-angiogenic drugs is debated because of not entirely encouraging
results from some clinical studies. After a preliminary assessment of the pathological and genomic
data, we will analyze the preclinical and clinical data in the anti-angiogenic approach in the therapeutic
management of these patients.
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2. BTC-Associated Angiogenesis and Lymphangiogenesis: From Pathological Features to
Genic Regulation
Angiogenesis and lymphangiogenesis are the biological processes that lead to the formation of new
vessels from pre-existing vascular and lymphatic vessels. In malignancies, tumor cells produce or lead
the microenvironment to the production of pro-angiogenic and lymphangiogenic signals able to recruit
and expand endothelial cells [13]. Angiogenesis and lymphangiogenesis have been investigated in
several gastrointestinal tumors [14–17]. Microvessel density (MVD) correlate with cancer progression,
metastasis, and prognosis in GBC [18], iCCA [19], and hilar CCA [20]. VEGF was expressed in 53.8%
and 59.2% of 236 iCCA and eCCA, respectively, even if it was significantly associated with intrahepatic
metastasis only in iCCA [21,22]. Furthermore, VEGF-A expression was evaluated in 111 iCCA cases and
compared between hilar and peripheral iCCA. The authors observed that VEGF-A was overexpressed
in peripheral cholangiocarcinoma (69% vs. 25%, p < 0.0001) and correlated with increased vascular
density [23]. This finding suggests a potential different imaging of hilar and peripheral iCCA and a
possible best response of peripheral iCCA to anti-angiogenic therapies. VEGF expression in eCCA
was associated with peritoneal recurrence and shorter survival [24]. Moreover, VEGF was significantly
associated with angiogenesis but not with patients survival [25] and prognosis [26] in GBC.
VEGF-A was express in around 80% of GBC, with 56.3% of 84 patients with a high expression,
resulting an independent prognostic factor of survival [27]. A meta-analysis of 102 different
immunohistochemical biomarkers, comprising epidermal growth factor receptor (EGFR), c-erb-B2
and VEGF-A [28], demonstrated that VEGF-A resulted more expressed in iCCA respect to eCCA
(RR: 2.78, 95% CI 1.69–4.58). Probably, the liver pro-angiogenic microenvironment may influence
this difference [29]. Tumor-associated macrophages, polarized toward the phenotype M2 by
several cytokines present in the tumor microenvironment, activate angiogenesis process through
the production of VEGF [30,31]. Conversely, interferon-γ (IFN-γ) inhibits the differentiation of
macrophages and favors the phenotype M1. When IFN-γ was intratumorally administered in a GBC
xenograft model subcutaneously injected with a human GBC cell line. MVD and VEGF concentration
were significantly reduced [32].
Another group assessed the role of VEGF-D both in GBC cell lines and in a xenograft mouse
model. An inhibitory effect both on proliferation and invasiveness was observed in vitro by using a
VEGF-D siRNA and confirmed in the subcutaneous and orthotopic xenograft tumors [33].
Moreover, lymphangiogenic VEGF-C and -D resulted overexpressed in a group of 50 GBC (>60%,
in 32 and 31 of 50 patients, respectively) and their high expression correlated with lymph node
metastasis via the nuclear factor (NF)-κB pathway [34,35], as observed in a small cohort of 20 patients.
In GBC, VEGF-C expression and MVD have been correlated with clinical outcomes
and pathological aspects. Sixty-three percent of 52 GBCs overexpressed VEGF-C protein by
immunohistochemistry. It was observed that the overexpression of VEGF-C was associated with
both worse outcomes and a higher incidence of lymph node metastasis, thus suggesting the role of
VEGF-C in promoting tumor progression via lymphangiogenesis [36].
VEGF-C expression was significantly correlated with lymphatic vessel involvement, lymph node
metastasis, and worse outcomes after operation (all p < 0.001), but not with MVD. By the Cox regression
model, lymphatic vessel involvement emerged as an independent prognostic parameter. These results
suggest that VEGF-C may play a role in tumor progression and lymph node metastasis in human GBC.
Beyond the effect of VEGF, the interplay of VEGF with angiopoietin (Ang)-1/2 and
thrombospondin (TSP-1) exerts a relevant pathogenic role in CCA. Tang et al. observed that VEGF and
Ang-2 might play a pro-angiogenic role, while TSP-1 may play an inhibitory role [21]. Ang-2 cooperates
with Ang-1 in the regulation of endothelial quiescence binding its receptor Tie-2. Its overexpression has
been related to the neovascularization process in several tumors. Voigtlander et al. observed that high
circulating levels of Ang-2 in CCA patients. The study demonstrated that this serum marker allows
the distinction of patients with CCA from those with biliary benign diseases thus suggesting the role
of this mediator in CCA pathogenesis [37]. The immunohistochemical analysis of 114 tissue specimens
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of CCA by the endothelial-specific antibody CD31 and the lymphoendothelial-specific antibody D2-40
demonstrated that an increased MVD is related to lower 5-year survival rates and to higher recurrence
rates [19].
Platelet derived growth factor (PDGF), that plays a key role in blood vessel formation, resulted
overexpressed in three CCA cell lines (OCA17, M156, and KKU100) and in human samples of CCA
(84.6%). In the same study Authors observed that expression of PDGF positively correlates with stage,
metastasis and short survival rate [38]. Another study, instead, demonstrated that the production of
PDGF-D by CCA cells favors the recruitment of cancer-associated fibroblasts (CAFs) exerting a key
role in the interplay between tumor and microenvironment. Particularly, PDGF-D promotes fibroblast
migration through PDGFRβ and Rho GTPase and JNK activation [39].
CD146 is a cell adhesion molecule (CAM) that also exerts a role in cellular processes as
signaling transduction, cell migration and angiogenesis [40]. In GBC patients, high CD146 expression
correlated with high microvessel and lymphatic vessel counts, in particular in poorly differentiated
adenocarcinoma, while peritumoral tissues, polyps, and chronic cholecystitis expressed lower levels
of CD146 and had lower average microvessel and lymph vessel counts. Moreover, a high CD146
expression and a high vessel counts correlated with a lower OS of GBC patients suggesting their
potential use as prognostic markers [41].
The last studies focus on the genomic landscape of BTC. Nakamura et al. characterized a large
BTC cohort (260 cases, including iCCAs, eCCAs and GBC) of Japanese patients by a combination of
whole-exome and transcriptome sequencing and uncovered molecular alterations. They identified 32
significantly altered genes, including potentially targetable genetic alterations in 40% of cases. FGFR2
fusion genes characterize iCCA cases while gene fusions involving the Protein Kinase CAMP-Activated
Catalytic Subunit Alpha (PRKACA) or Protein Kinase CAMP-Activated Catalytic Subunit Beta
(PRKACB) preferentially occurred in eCCA [42,43]. In GBC, inactivation of PTEN and TSC1 was
frequently observed while EGFR family genes (EGFR, ERBB2 and ERBB3) were activated. Next
generation sequencing led to the observation that KRAS mutations are characteristic of pCCA (22%
to 53%), while isocitrate dehydrogenase (IDH)1/2 mutations are more common in iCCA [44,45].
Mutations of TP53 and SMAD4 have been observed in liver-fluke associated CCA while BAP1 and
IDH1/2 were more often mutated in non-liver fluke associated CCA [46]. Furthermore, genomic
studies confirmed that molecular pathways driving cell growth and angiogenesis, as EGF, RAS, AKT,
and MET, are activated in BTCs [47] (Table 1). Lastly, the role of microRNAs (miR)s, small noncoding
RNAs, has been suggested in the promotion of angiogenesis [48,49]. The only available data concern
the miRNA101 that binds directly to the 3’-untranslated region (UTR) of both VEGF and COX-2
mRNAs as demonstrated by both computational analysis and experimental assays. miR-101 inhibits
angiogenesis both in vitro and in vivo [50]. The incubation of human umbilical vein endothelial cells
with the conditioned media collected from human CCA cells transduced with the miR-101 is associated
to an anti-angiogenic effect when conditioned media from CCA cells overexpressing miR-10 were
mixed with Matrigel and subcutaneously injected in C57BL/6 mice.
Table 1. Genomic aberrations of biliary tract cancers (BTCs) linked to the angiogenesis and correlated
to the location of tumors.
Subtype of BTC Genomic Aberrations
iCCA
FGFR2 fusion genes
IDH1/2 mutations
pCCA KRAS mutations
eCCA PRKACA and PRKACB fusion genes
GBC
PTEN (inactivated)
TSC1 (inactivated)
EGFR, ERBB2 and ERBB3 (activated)
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Overall, these data suggest the existence of several molecules and mechanisms involved in the
angiogenic process and the potential therapeutic role of drugs targeting the pro-angiogenic signaling
pathways in tumors of the biliary tract (Figure 1).
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3. Molecular Pathways Involved in Angiogenesis
3.1. VEGF Pathway
VE F is the ost relevant pro-angiogenic protein. Indeed, the signaling ediated fro VE F
pro ote the proliferation, differentiation and igration of EC representing the pivotal echanis
both physiologically and in solid tumors [21]. The main sti ulus for VEGF production is represented
by hypoxia that leads to the expression of the transcription factor hypoxia inducible factor (HIF)1-α.
Although tumor cells usually represent the major source of VEGF, tumor-associated stroma is also
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an important site of VEGF production [51]. The VEGF family is composed by six structurally related
proteins that bind three different cell surface-expressed receptors (VEGFR-1/2/3). VEGFR-1 and -2 are
mainly expressed on endothelial cells while VEGFR-3 in the lymphatic endothelium [52].
The major pro-angiogenic signal is generated from the ligand-activated VEGFR-2 that binds
phospholipase (PL)-Cγ and activates protein-kinase C (PKC). This mechanism activates MAPK through
a MEK-dependent mechanism and independently from RAS [53]. Other studies suggest that VEGF
effect is also mediated by RAS activation that is essential for DNA synthesis both basally and after
VEGF stimulation [54]. VEGFR-2 also activates phosphatidylinositol 3′-kinase (PI3K), which results in
an increase of the lipid phosphatidylinositol (3,4,5)P3 and consequent activation of protein kinase B
(Akt/PKB), endothelial nitric oxide synthase, and the small GTP-binding protein Rac [55].
3.2. MEK/ERK Pathway
The MEK/ERK pathway also exerts a pro-angiogenic effect in tumors and represents another
potential target of anti-angiogenic drugs in BTCs. The role of this pathway in promoting angiogenesis
is mainly related to the phosphorylation of eukaryotic translation initiation factor 4E-binding protein 1
(4E-BP1), S6-kinase (S6K), and MAP kinase interacting kinase (MNK) mediated by ERK. This process
leads to an increased rate of mRNA translation into HIF-1α protein that is the main transcriptional
inductor of several pro-angiogenic factors such as VEGF. ERK is also able to activate the transcription
of HIF-1α by the co-activator CBP/p300 that increases HIF-1α/p300 complex formation [56].
3.3. Other Signaling Pathways
Another signaling pathway involved in the pathogenesis of CCA is the Yes-associated protein
(YAP)/Hippo pathway. YAP regulates the expression of genes regulating proliferation, apoptosis and
angiogenesis and is overexpressed in CCA cells. Particularly, YAP promotes the angiogenesis process
interacting with TEAD transcription factors that have as transcriptional target the pro-angiogenic
microfibrillar-associated protein 5 (MFAP5) [57]. CD31+ and MFAP5 expression was studied in
xenograft models and was correlated to YAP activity [57].
NF-kB, signal transducer and activator of transcription (STAT)-3 and activator protein (AP)-1
also regulate the expression of various genes involved in proliferation, apoptosis, inflammation
and angiogenesis [58,59] thus representing potential therapeutic targets of anti-angiogenic drugs.
Particularly, STAT3, when constitutively activated, as in experimental models, causes an enhanced
expression of VEGF [58].
Histamine also plays a role in regulating the cell growth in CCA. It acts via four receptors (HRH1,
HRH2, HRH3, and HRH4) and, particularly, its binding to HRH3 is involved in CCA cancerogenesis
interfering with VEGF signaling [60].
4. Preclinical Studies
4.1. Targeting the VEGF Pathway
Bevacizumab, a monoclonal antibody (mAb) neutralizing VEGF, was tested in a preclinical
model of CCA, in which it exerted an anti-angiogenic effect through the inhibition of both the
peri- and intra-tumoral vascularization resulting in the reduction of tumor growth. On the other
side, bevacizumab led to an overexpression of HIF1α and HIF1α-responsive genes, involved in
drug resistance mechanisms [61]. This is the only study exploring, in a preclinical setting, the
anti-tumor effect of bevacizumab in BTC, although several clinical studies tested this drug in BTC, as
reported below.
The multikinase inhibitor sorafenib, targeting VEGFR, platelet growth factor receptor (PDGFR)
and RAF kinase, has been evaluated in a preclinical model of iCCA showing a relevant antitumor
effect. Sorafenib inhibits the phosphorylation of MEK, MAPK and STAT3 while, in vivo, the oral
administration of sorafenib inhibits the growth of subcutaneous tumors and prolongs the survival
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of mouse models with peritoneally disseminated disease [62]. Sorafenib-coated metal stents have
been evaluated in vitro on HuCC-T1 cells and in vivo in a mouse xenograft model [63]. Cancer cells
were seeded onto the polymer film and then allowed to proliferate. At a concentration higher than
10 mM the drug inhibited the tube formation of endothelial cells in vitro. Cell invasion also was
completely inhibited at a dose of sorafenib higher than 25 mg/mL and migration was inhibited in
a dose-dependent manner. The effects on both invasion and migration were maintained during the
30-day drug release experiment. The antitumor effect of sorafenib-coated stents was evaluated in vivo
by using a mouse tumor xenograft model obtained by the subcutaneous injection of HuCC-T1 cells.
When sorafenib-coated stents were placed under the tumor mass the growth of the tumor was reduced
and the expression of molecules involved in apoptosis and mitosis signaling, such as B-cell lymphoma
(Bcl)-2, Bcl-x, caspase-3 was significantly influenced by the sorafenib-coated stents [63].
Vandetanib, a VEGFR-2 and EGFR tyrosine kinase inhibitor, was tested in bioluminescent CCA cells
and mouse xenograft models of CCA [64]. TKKK cell line, one of the four CCA cell lines investigated
in this study, characterized by the highest expression of both EGFR and VEGF, was more sensitive to
vandetanib [64]. In a subcutaneous xenograft model injected with TKKK cells, both the anti-tumor and
anti-metastatic effect of vandetanib was demonstrated confirming the in vitro data [64] and suggesting
that a particular setting of CCA, characterized by EGFR amplification and lack of K-RAS mutations,
could benefit by the clinical employ of vandetanib. The immunohistochemical study of tumors from
the TKKK xenografts showed a significant reduction of both MVD and Ki67 proliferation index.
Another preclinical study evaluated the anti-tumor properties of axitinib, an oral specific
VEGFR-1/2/3 tyrosine kinase inhibitor, in CCA. Authors screened eight CCA cell lines for expression
of angiogenesis-related molecules by gene expression analysis and found that VEGF-A, VEGF-B,
VEGF-C and VEGF-D were highly expressed in three cell lines [65]. Two of these cell lines were then
used to obtain subcutaneous xenograft models and the MVD was studied to explore the anti-angiogenic
effect of axitinib. This drug significantly reduced both the tumor growth and the neo-angiogenesis in
xenograft models [65].
4.2. Targeting the MEK/ERK Pathway
An orthotopic model of GBC, obtained by inoculation of K-RAS mutated NOZ cells, was used to
test the efficacy of the MEK inhibitor U0126 [66]. The intraperitoneal injection of this drug significantly
increased the survival of the mice orthotopically injected with NOZ cells, thus suggesting a new
therapeutic strategy for advanced GBC.
A combination therapy targeting both EGFR and MEK1/2 was tested in vitro and in vivo
revealing a promising therapeutic strategy for biliary tract carcinoma. In vitro, the eCCA EGI-1,
WITT cell lines and the iCCA MTCHC01 cell line were treated with panitumumab, trametinib or
their combination. Trametinib was effective to inhibit MAPK-1 and -2 activation in all cell lines,
characterized by different mutational status of K-RAS, while panitumumab was particularly able to
reduce phospho-EGFR expression in K-RAS mutated EGI-1 cells and the MAPK signaling in K-RAS
wild type WITT cells [67]. In vivo, the monotherapy with trametinib showed antitumor properties
only in xenograft models subcutaneously injected with K-RAS mutated cells. The combination of
trametinib with panitumumab did not potentiate the activity of trametinib in EGI-1 xenografts but
the combination treatment was essential to slow the tumor growth in WITT xenografts, probably
because this TKi is essential to overcome the resistance to panitumumab in the K-RAS wild type
xenografts. The ant-iangiogenic effect was studied in vivo by the evaluation of CD31 expression and it
was observed that trametinib and the combination therapy significantly reduced the CD31 expression
in K-RAS mutated xenografts while in K-RAS wild type xenografts none of the treatments influenced
the expression of this angiogenesis marker. However, the significant reduction of CD31 expression
obtained by panitumumab alone in MT-CHC01 xenografts was associated to a paradoxical increased
tumor growth. Consequently, the authors suggested that the anti-tumor and anti-angiogenic effect
were independent, and that angiogenesis reduction was not enough to inhibit tumor growth [67].
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4.3. Other Drugs
Curcumin, a natural phenol with anti-inflammatory properties, derived from turmeric (Curcuma
longa), inhibits several transcription factors involved in CCA pathogenesis, such as NF-κB, signal
transducer and activator of transcription (STAT)-3 and activator protein (AP)-1. Curcumin showed
anti-proliferative and pro-apoptotic effects in CCA cell lines and decreased tumor development
in a hamster model of CCA with higher survival rates. In this model the authors observed the
anti-angiogenic properties of curcumin represented by the reduction of MVD and the suppression of
VEGF expression, beyond the effects on cell proliferation, tumor invasion and apoptosis [68,69].
In a CCA xenograft mouse model, obtained by the subcutaneous injection of Mz-ChA-1
cells, the inhibition of histamine decarboxylase, that is responsible of histamine formation from
histidine, downregulated the autocrine stimulation of histamine on tumor growth (~80%) and VEGF
expression [70]. RAMH ((R)-(α)-(−)-methylhistaminedihydrobromide) is a HRH3 agonist and its
antitumor effect was studied in vitro and in vivo. In vivo, RAMH inhibited tumor growth in Mz-ChA-1
xenografts and reduced the expression of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 in tumor
samples [71].
Lastly, tymoquinone, a derived from black cumin (Nigella stativa), exerts antitumor properties in
cholangiocarcinoma models. In vitro and in vivo studies demonstrated that tymoquinone reduces
the expression of COX-2, VEGF and cyclin B1, inhibiting the DNA-binding activity of NF-κB, thus
reducing cell survival and proliferation [72].
These data suggest that the inhibition of angiogenesis has a good rationale in the therapeutic
management of BTC. Indeed, the data are still lacking and several aspects, like those related to the drug
resistance mechanisms, need to be clarified. Mechanisms of resistance are related both to cells of the
microenvironment, as the myeloid cells that promote a VEGF-independent tumor angiogenesis [73],
and to intrinsic tumor mechanisms, as the angiogenic signaling redundancy [74]. Moreover, although
the anti-angiogenic therapy is promising, the recognition of markers of responsiveness or development
of evasion to anti-angiogenic therapy is crucial for a personalized treatment of BTCs.
5. Clinical Studies in BTC Patients: Is There a Chance for a Phase III Trial?
Because of the relevance of angiogenesis in the development of BTCs and the data from preclinical
studies, the activity of many anti-angiogenetic treatments with both antibodies (bevacizumab and
ramucirumab) or trap (aflibercept) and TKIs (sorafenib, vandetanib, sunitinib, and regorafenib) were
explored alone or in association to chemotherapy and/or anti-EGFR drugs in several phase I and II
trials (Table 2).
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Table 2. Clinical trials of anti-angionenic drugs in BTC.
Drug Design Regimen Main Inclusion Criteria Primary Outcomes Status Results Reference
mAb Phase II Bevacizumab + GEMOX Metastatic BTC PFS Terminated mPFS: 7.0 months;PFS rate: 63% [75]
mAb Phase II Bevacizumab + CT +erlotinib Metastatic BTC Response rate Terminated
PR:12%; SD: 51%; mOS:
9.9 months; TTP: 4.4 months [76]
mAb Phase II Bevacizumab + FOLFIRI
Second line therapy in
GEMOX pretreated
m-iCCA
Tolerance and efficacy Terminated
PR: 5/13 pts; SD 6/13 pts;
mPFS: 8 months; mOS:
20 months
[77]
mAb Randomizedphase II
Bevacizumab vs.
panitumum +
oxaliplatin/gemcitabine/
capecitabine
Untreated advanced or
metastatic K-RAS
wild-type (WT) BTC
6-month survival rate;
6-month
progression rates
Ongoing Not achieved [78]
mAb Phase II Bevacizumab +FOLFOX Advanced BTC Safely
Closed for slow
accrual Not drawn [79]
mAb Phase II
Bevacizumab +
gemcitabine +
capecitabine
Advanced or metastatic
adenoca. of gallbladder or
biliary ducts
Safety/efficacy Ongoing Not achieved [80]
mAb Phase II Ramucirumab Advanced, pre-treatedBTCs Safety/efficacy Ongoing Not achieved [81]
mAb Phase I Ramucirumab +pembrolizumab Metastatic BTC Safety/DLT Ongoing Not achieved [82]
mAb Phase II
Ramucirumab vs.
merestinib +
cisplatin/Gemcitabine
Advanced or metastatic
BTC PFS Ongoing Not achieved [83]
VEGF
trap Phase I
Aflibercept +
capecitabine
Chemorefractory
metastatic BTC DLT/MTD On going Not achieved [84]
TKI Phase II Sorafenib Advanced BTC Disease control rate at12 weeks Terminated
Disease control rate at
12 weeks: 32.6%; mPFS:
2.3 months; mOS: 4.4 months
[85]
TKI Phase II Sorafenib Advanced BTC Objective responserate
Closed for not
achieved primary
objective
Response rate: 0%; SD: 39%;
PFS: 3 months; OS: 9 months [86]
TKI
Double-blind
randomized
phase II
Sorafenib + gemcitabine
vs. placebo +
gemcitabine
Unresectable or metastatic
mBTC PFS Terminated
PFS: 4.9 vs. 3.0 months
(p = 0.859); mOS: 11.2 vs.
8.4 months (p = 0.775)
[87]
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Table 2. Cont.
Drug Design Regimen Main Inclusion Criteria Primary Outcomes Status Results Reference
TKI Phase II Sorafenib +gemcitabine/cisplatin mBTC first-line therapy 6-month PFS Terminated
6-month PFS: 51%, mPFS:
6.5 months; mOS: 14.4 months [88]
TKI Phase II Sorafenib + erlotinib mBTC first-line therapy PFS
Stopped for failure
to meet the main
requirement
Unconfirmed PR: 2/13; mPFS:
2 months; mOS: 6 months [89]
TKI Phase I/II Sorafenib + GEMOX Advanced BTC Safely Closed for slowaccrual Not drawn [90]
TKI Phase I/II Sorafenib +capecitabine/Oxaliplatine Advanced BTC Safety/efficacy Ongoing Not achieved [91]
TKI Umbrellaphase I/II trial
Sorafenib vs. other TKI
+ GEMOX
Advanced or metastatic
GBC or eCCA Safety/efficacy Ongoing Not achieved [92]
TKI Phase I Vandetanib +gemcitabine/capecitabine mBTC MTD/safety Terminated
Vandetanib 300 mg daily;
good safety profile [93]
TKI Randomizedphase II
Vandetanib vs.
vandetanib +
gemcitabine vs.
gemcitabine
Advanced BTC mPFS Terminated mPFS: 105 vs. 114 vs.148 days (p = 0.18) [94]
TKI Randomizedphase II
Cediranib vs. placebo +
cisplatin/gemcitabine Advanced BTC mPFS Terminated
mPFS: 8 vs. 7.4 months
(p = 0.72) [95]
TKI Phase II Sunitinib Second line unresectable,metastatic BTC Safety/efficacy Terminated
mTTP: 1.7 months; Objective
RR: 8.9%; Grade 3–4 toxicities
in 46.4% of patients
[96]
TKI Phase II Sunitinib Advanced CCA PFS/ORR Ongoing Not achieved [97]
TKI Phase II Regorafenib mBTC with no more than2 prior lines CT 6-month OS rate Ongoing Not achieved [98]
TKI Phase II Regorafenib advanced, metastatic BTC,after first-line CT PFS Ongoing Not achieved [99]
TKI Phase Ib/II Regorafenib + GEMOX advanced BTC MTD/safety Ongoing Not achieved [100]
TKI Phase II Selumetinib metastatic BTC PFS Terminated mPFS: 3.7 months [101]
GEMOX: gemcitabine/oxaliplatin; FOLFOX: folinic acid/fluorouracil/oxaliplatin; CT: chemotherapy; TKI: tyrosine kinase inhibitor; mPFS: median progression free survival; PFS:
progression free survival; DLT: dose limiting toxicity; OS: overall survival; PR: partial response; SD: stable disease; CCA: cholangiocarcinoma; MTD: maximum tolerated dose.
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5.1. Bevacizumab
In a phase II study, it was administrated with gemcitabine and oxaliplatin in 35 patients with
untreated metastatic BTC with a favorable toxicity profile. Median progression free survival (PFS) was
7.0 months (95% CI 5.3–10.3), even if six-month PFS rate was 63% (47/79 patients), below the targeted
rate of 70% [75]. Combination of bevacizumab with different chemotherapy and erlotinib (a TKI that
inhibits EGFR) was evaluated in a multicenter phase II trial enrolling 49 patients. In this study, 12%
and 51% of patients achieved a partial response and a stable disease, respectively. Median OS and
TTP were 9.9 and 4.4 months, respectively, in the absence of severe adverse events. The Authors
demonstrated that this combination might represent a therapeutic option in patients with metastatic
BTC. However, the stratification performed for the molecular analysis of EGFR pathway showed that
patients whose tumors had mutations in EGFR vIII, or had non-wild-type K-RAS may be less likely to
respond to erlotinib treatment [76]. Bevacizumab was evaluated as second line therapy in association
with FOLFIRI in 13 GEMOX pretreated metastatic (m)BTC patients. Five and six patients achieved
partial response (PR) and stable disease (SD), respectively, with acceptable toxicities. Median PFS and
mOS were 8 (95% CI: 7–16) and 20 (95% CI: 8–48) months, respectively. Response and disease control
rates were 38.4% (95% CI: 12.5–89) and 84.5% (95% CI: 42–100), respectively [77]. An ongoing phase II
randomized study will evaluate as primary end-point the survival and progression rates at six months
in untreated advanced or metastatic K-RAS wild-type (WT) BTC patients treated with gemcitabine,
oxaliplatin and capecitabine combination plus panitumumab or bevacizumab (GOC-B-P). Secondary
end-point will be OS and response rate before cross-over; moreover, PFS and response rate will be
evaluate after cross-over [78]. A phase II trial examined the activity of bevacizumab with FOLFOX-6
but the patients enrolled were too few to draw conclusions [79]. Another study evaluated the effect of
bevacizumab with gemcitabine plus capecitabine combination [80] but results are not still available.
5.2. Ramucirumab
Activity of ramucirumab, a monoclonal anti-body direct against VEGFR 2, is actually being
evaluated in a phase II study enrolling patients with pre-treated BTC. Primary outcome is PFS
calculated as the time period from treatment start to disease progression or death, whichever occurs
first, or to the last follow-up if no progression has being achieved [81]. A phase I trial is evaluating
the safety and dose-limiting toxicities (DLT) for association of ramucirumab with pembrolizumab
(an immunochekpoint inhibitor) in many cancer including BTC [82]. A phase II study is randomizing
untreated advanced or metastatic BTC to receive ramucirumab or merestinib (a MET inhibitor) or
placebo plus cisplatin/gemcitabine, with PFS as primary outcome measure, and with overall survival
(OS), objective response rate (ORR), disease control rate (DCR), as main secondary endpoints [83].
5.3. Aflibercept
Aflibercept, a VEGF trap, is being tested in a phase I trial, associated with capecitabine in
chemorefractory metastatic breast and digestive cancers, including BTC (MOMENTUM1). This study
aims to assess the DLT and the maximum tolerated dose (MTD) in both metronomic or intermittent
arms to define the recommended dose for the phase II trial [84].
5.4. Sorafenib
Sorafenib has been examined in several phase II trials in untreated patients with mBTC. Sorafenib
monotherapy achieved disappointing results in two phase II trials. In the first, this TKI administered
alone in 46 patients showed a disease control rate at 12 weeks of 32.6% with a mPFS and a mOS of
2.3 and 4.4 months, respectively, with an acceptable toxicity profile [85]. The second study, a phase II
trial with sorafenib alone, was closed because the primary objective was not reached. The response
rate was 0% (0%–11%), with 39% of patients with a SD. PFS and OS were three and nine months,
respectively [86].
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Combination therapy with chemotherapy and sorafenib or other TKIs was a failure.
A double-blind phase II Working Group of Internal Oncology (AIO) study randomizing 102 patients
with uresectable or metastatic BTC to gemcitabine with sorafenib or placebo did not showed an
improved efficacy from the addition of the TKI. PFS and OS did not differ in two arms. A multivariate
analysis showed that patients with liver metastasis and undergone resection of primary site survived
longer if treated with sorafenib than placebo (p = 0.019). Moreover, in sorafenib arm, patients with
hand-foot syndrome (HFS) showed longer PFS and OS than patients without HFS [87]. A phase II study
evaluated the addition of sorafenib to gemcitabine and cisplatin in metastatic (m)BTC first-line therapy.
Six-month PFS was 51%, with amPFS and mOS of 6.5 (95% CI: 3.5–8.3) and 14.4 months (95% CI:
11.6–19.2 months), respectively. All these data are worse compared to the historical achievement of
platinum-based therapy, with an increased toxicity [88]. The phase II trial of Southwest Oncology
Group (SWOG), which enrolled 34 patients with mBTC receiving sorafenib and erlotinib, was stopped
because it failed to meet the requirement of at least 13 patients alive and without progression after
four months from recruitment [91]. Actually, a phase I/II study of combination of gemcitabine and
oxaliplatin (GEMOX) with sorafenib was concluded but the number of participants is too small to
draw significant conclusions [90]. The combination of capecitabine and oxaliplatin with sorafenib was
also studied in a phase I/II study but results are not still available [91]. An umbrella phase II trial
evaluating several small molecules including sorafenib in association with GEMOX after the result
of genomic and proteomic profiling of tumor tissue is actually ongoing for advanced or recurrent
BTC [92].
5.5. Vandetanib
Vandetanib is a strong inhibitor of VEGFR-2 evaluated in one phase I trial and two large phase II
trials. The maximum tolerate dose (MTD) and safety of vandetanib in association with gemcitabine
and capecitabine have been evaluated in 23 mBTC patients. This combination was well tolerated
with a recommended phase II dose of gemcitabine 1000 mg/m2 weekly for three consecutive weeks,
capecitabine 850 mg/m2 BID dys 1–21, and vandetanib 300 mg daily, every 28 days [93]. In an Italian
phase II trial, 173 patients with advanced BTC were randomized into three arms: vandetanib alone,
vandetanib plus gemcitabine, and gemcitabine plus placebo. A mPFS of 105 (72–155), 114 (91–193) and
148 (71–225) days, respectively, was achieved without a statistical significant differences (p = 0.18), and
with similar adverse events for the three groups [94].
5.6. Cediranib
In a multicenter phase II study, 124 patients were randomized to receive first-line cisplatin and
gemcitabine chemotherapy with either 20 mg oral cediranib or placebo. Median PFS was 8.0 and
7.4 months, in cediranib and placebo group, respectively, without a statistical significance (HR 0.93;
p = 0.72). Patients who received cediranib had more grade 3–4 toxic effects [95].
5.7. Sunitinib
An Asiatic phase II multicenter trial evaluated the activity of sunitinib, a multitarget TKI acting
on angiogenesis, in 56 patients with pretreated mBTC. A marginal efficacy was observed since a
median time to progression (TTP) of 1.7 months (95% CI 1.0–2.4) and a disease control rate of 50%
was achieved [96]. In a report of three cases of patients with advanced ICC pretreated with standard
chemotherapy, treatment with sunitinib achieved a sustained disease control superior to four months
with either a PR or SD with a manageable side effect [102]. An ongoing single arm, phase II trial is
evaluating mOS as primary end-point and PFS and ORR as secondary end-point in patients with
advanced CCA treated with sunitib after a first line with chemotherapy [97].
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5.8. Regorafenib
Regorafenib is another TKI that inhibits VEGFRs and TIE2. In a phase II trial, patients with mBTC
that underwent no more than two prior lines of systemic chemotherapy are being enrolled to receive
this drug. Primary end-point will be six-month OS rate with disease control rate and six-month PFS
rate as secondary end-points [98]. In a similar phase II study, regorafenib is evaluated in advanced
and metastatic BTC patients after the failure of a first-line chemotherapy. Primary and secondary
outcomes were PFS, ORR, OS, and biomarkers changes, respectively [99]. Another study will analyze
the combination of this TKI with GEMOX. Another ongoing phase Ib aims to identify the regorafenib
dose associated to limiting toxicities during and within two cycles of treatment and to assess the right
dose for the phase II study [100].
5.9. Selumetinib
The MEK1/2 inhibitor Selumetinib was evaluated in 28 patients with the response rate as primary
endpoint. Sixty-eight percent of patients experienced a stable disease. Median PFS was 3.7 months
while the median OS was 9.8 months. Rash (90%) and xerostomia (54%) were the most relevant side
effects [101]. Another phase II study testing selumetinib with Cisplatin/Gemcitabine is recruiting
patients and has as primary endpoint the change in tumor size [103].
5.10. Phase III Trials
Currently, there are neither closed nor ongoing posted phase III clinical trials testing
anti-angiogenic drugs in mBTC. Considering that there are more negative than positive results from
phase II non-randomized and randomized trials, we would consider far away a large-sample study.
The failure to achieve the primary and secondary end-point may be due to the need to select population
on the basis of cancer expression of the targets of these biological agents. In the future, the use of
umbrella trials could be a turning point for the use of anti-angiogenic drugs in this malignancy.
6. Conclusions
Angiogenesis and lymphangiogenesis are crucial in the carcinogenesis of BTCs. Several studies
confirmed an overexpression of molecules involved in the formation of new vessels on tumor samples
and a correlation with a worse prognosis both in CCA and GBC. Alterations of genes involved
in the angiogenic process, such as FGFR2, characterize these tumors and could interfere with the
interplay between VEGF, TSP-1 and Ang-1/2. Different preclinical studies tested the effect of new
anti-angiogenic drugs in BTCs with contrasting results, partially due to unknown drug resistance
mechanisms. Furthermore, the role of new drugs in inhibiting the lymphangiogenesis has not been
well elucidated and these aspects remain obscure. Moreover, phase I and II trials did not lead to
encouraging results. Since BTCs include a large spectrum of different diseases, as confirmed from
the recent genomic studies, these data suggest the need of trials enrolling selected patients. Indeed,
the identification of patients with a hyperactivation of the pro-angiogenic pathways or with specific
genic aberrations could identify a defined setting of patients that could benefit of the treatment with
targeted therapies.
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